Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
The aim of this work was to evaluate the postoperative serum markers of type I collagen synthesis (PINP,PICP) and degradation (ICTP) and their possible potential for predicting the spread of disease and survival. 373 node-positive breast cancer patients were enrolled. 120 patients (32%) developed recurrent disease in the follow-up. The mean time to recurrence was 17 months and the mean follow-up time was 45 months. The mean level of PINP was significantly elevated in the patients who developed metastatic disease in the follow-up as compared with those without metastases. PINP was statistically significantly higher in all the patients who developed bone metastases than in those without metastases. When patients with only bone metastases or patients with bone and soft tissue and/or visceral metastases and patients with only visceral or soft tissue metastases were compared with those not exhibiting metastases, PINP was significantly higher in the group with recurrence in the bone, but there were no significant differences in serum PINP, PICP or ICTP values between the patients with only bone metastases and those who developed soft or visceral metastases during the follow-up. Postoperative high PINP was also a factor for poorer survivaL Tumor size, malignancy grade and progesterone receptors were shown in multivariate analysis to be predictors of recurrence and tumor size and PINP and progesterone receptors to be predictors of survivaL
Jukkola
A
A
Department of Oncology, University of Oulu, Finland.
Bloigu
R
R
Holli
K
K
Joensuu
H
H
Valavaara
R
R
Risteli
J
J
Blanco
G
G
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000556:secondary; D001943:Breast Neoplasms / Q000097:blood* / Q000737:chemistry / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D024042:Collagen Type I; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005109:Extracellular Matrix / Q000378:metabolism; D005387:Finland / Q000453:epidemiology; D005500:Follow-Up Studies; D008207:Lymphatic Metastasis; D008408:Mastectomy; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D010455:Peptides; D011347:Procollagen / Q000097:blood*; D011379:Prognosis; D011446:Prospective Studies; D011980:Receptors, Progesterone / Q000032:analysis; D012983:Soft Tissue Neoplasms / Q000097:blood / Q000556:secondary; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D017312:Toremifene / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D024042:Collagen Type I; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; D011980:Receptors, Progesterone; C052929:collagen type I trimeric cross-linked peptide; C047202:procollagen Type I N-terminal peptide; C042813:procollagen type I carboxy terminal peptide; D013629:Tamoxifen; D017312:Toremifene